Health System AI Steering Committee Meeting Agenda Template

What a Health System AI Steering Committee Does

The committee provides organization-wide oversight for AI tools and agents used in clinical and operational settings. It sits at the intersection of patient safety, technical risk, regulatory obligation, and operational readiness. Rather than treating AI as a one-time procurement decision, the group maintains continuous visibility into what is deployed, how it performs, and where residual risk remains.

Members commonly include clinical leadership, IT and security, compliance and legal, and data science or AI operations. That mix ensures decisions reflect workflow impact, infrastructure controls, regulatory documentation, and model lifecycle management at the same time.

Core Functions and Responsibilities

In practice, core responsibilities cluster around four areas:

• Approval and intake: evaluating new tool and agent requests before broad deployment.
• Risk management: reviewing known issues, residual risk, and mitigations tied to live systems.
• Inventory and change control: keeping an accurate record of models, tools, agents, and material updates.
• Compliance checkpoints: confirming documentation and controls align with internal policy and external obligations, including items such as HTI-1 documentation and FDA classifications where relevant.

These functions are easier to sustain when the meeting agenda is stable. Standing items create a repeatable review rhythm; ad hoc items absorb exceptions without rewriting the entire process each month.

Reusable Meeting Agenda Template

Use the structure below as a starting point for recurring meetings. Keep standing items first so inventory, risk, and compliance stay visible even when the meeting runs long. Place new requests and incident review after those standing items so exceptions do not crowd out baseline oversight.

Decision Authority and Escalation Paths

An agenda is only effective when the committee knows what it can decide in-session and what must escalate. Clarify in advance which approvals the steering committee owns, which require executive or clinical executive sign-off, and which technical controls sit with IT or security. Escalation paths should cover safety concerns, security findings, unresolved compliance gaps, and tools introduced outside standard procurement.

Document decisions with enough context for later audit: what was reviewed, what was approved or deferred, owners for follow-up, and any conditions attached to continued use.

Practical Considerations for Recurring Meetings

The following practices help keep recurring meetings useful as the AI portfolio expands:

• Separate standing agenda items (inventory, risk review, compliance checkpoint) from ad hoc items (new requests, incident review) to keep meeting length predictable.
• Align meeting cadence with regulatory reporting windows, such as HTI-1 compliance checkpoints, so documentation is reviewed before external deadlines rather than after.
• Confirm a mechanism exists to capture third-party or embedded AI agents introduced outside the standard procurement process.
• Retain documentation reviewed in meetings, including source attributes, validation results, and incident logs, in a form that supports audit and regulatory inquiry.
• Review committee membership periodically to confirm clinical, IT/security, compliance, and data science roles remain represented as tool inventory grows.

Runtime Oversight Between Meetings

Committee meetings create a governance cadence; they do not replace day-to-day monitoring. Between sessions, runtime signals (inventory drift, performance changes, incidents, and control failures) should feed the next standing risk and inventory reviews. Without that operational backbone, the agenda becomes a discussion checklist rather than a reliable oversight mechanism.

Teams that treat runtime governance as an input to the steering committee can keep meeting time focused on decisions: what to approve, what to constrain, what to remediate, and what to escalate.